Scientists Identify Hidden T Cell Brake That Explains Why Immunotherapy Fails

Cancer immunotherapy has transformed oncology over the past decade, enabling the immune system to recognize and destroy tumor cells with remarkable precision. But for a significant proportion of patients, the treatment simply does not work — and doctors have long struggled to explain why. A discovery published this week in Nature may finally provide an answer.

Researchers have identified a previously unknown mechanism that acts as a molecular brake on T cells — the immune systemu2019s cancer-fighting soldiers — preventing them from mounting an effective attack even when immunotherapy is administered. The findings could open the door to new combination therapies designed to release that brake and restore treatment sensitivity.

The study focused on a protein called SLAMF6, which was found to accumulate on the surface of T cells in patients whose tumors resisted immunotherapy. In laboratory models, blocking SLAMF6 restored T cell activity and shrank tumors that had previously been unresponsive. The team described the protein as a u201chidden checkpointu201d — distinct from the well-known PD-1 and CTLA-4 targets of existing drugs, but functionally similar in its ability to suppress immune responses.

u201cWe have been targeting known checkpoints for years with impressive results, but a large subset of patients never respond,u201d said the studyu2019s lead author. u201cThis finding suggests there are additional layers of immune suppression we have not yet addressed. SLAMF6 is one of them.u201d

The research consortium analyzed tissue samples from more than 800 patients across multiple cancer types, including melanoma, lung cancer, and colorectal cancer. In each case, elevated SLAMF6 expression correlated strongly with poor outcomes following immunotherapy, regardless of tumor stage or patient demographics.

If the results translate to human trials, oncologists could screen patients for SLAMF6 levels before starting treatment, identifying those most likely to benefit from a SLAMF6 inhibitor added to their regimen. Pharmaceutical companies have already expressed interest in developing antibodies against the protein.

The discovery adds to a growing body of evidence that the immune systemu2019s interaction with cancer is far more complex than early immunotherapy models suggested. Researchers now speak of a network of inhibitory pathways, each potentially targetable, rather than a single on-off switch.

Clinical trials testing SLAMF6 inhibitors are expected to begin within the next 18 months. Until then, the research team cautions against drawing premature conclusions, noting that findings in cellular and animal models do not always translate directly to human patients.

The study was supported by grants from the National Cancer Institute and the Parker Institute for Cancer Immunotherapy.